HYPERTENSION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

常染色体显性多囊肾病中的高血压

基本信息

批准号：
6270576
负责人：
ROBERT W SCHRIER
金额：
$ 17.37万
依托单位：
UNIVERSITY OF COLORADO DENVER
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
起止时间：
1998-04-01 至 1999-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/6270576
关键词：
angiotensin /renin /aldosterone hypertension autosomal dominant trait blood chemistry blood pressure cardiovascular disorder chemotherapy chlorothiazide clinical research dietary sodium enalapril female genetic polymorphism genotype human subject human therapy evaluation hypertension longitudinal human study pathologic process peptidyl dipeptidase A plethysmography polycystic kidney preeclampsia pregnancy toxemia /hypertension spironolactone tomography ventricular hypertrophy

angiotensin /renin /aldosterone hypertension autosomal dominant trait blood chemistry blood pressure cardiovascular disorder chemotherapy chlorothiazide clinical research dietary sodium enalapril female genetic polymorphism genotype human subject human therapy evaluation hypertension longitudinal human study pathologic process peptidyl dipeptidase A plethysmography polycystic kidney preeclampsia pregnancy toxemia /hypertension spironolactone tomography ventricular hypertrophy

展开

项目摘要

Hypertension occurs commonly and early in the natural history of autosomal dominant polycystic kidney disease (ADPKD). Hypertension (HBP) has been shown to have an adverse effect on both patients and renal outcome in ADPKD. Moreover, left ventricular hypertrophy (LVH), a known risk factor for cardiovascular mortality and sudden death, occurs frequently in HBP ADPKD patients. At present it is not clear what is the optimal level of blood pressure reduction in HBP ADPKD patients to minimize loss of renal function or to reverse lVH. Given that hypertension is the most important treatable variable to affect renal and patients outcome in ADPKD, this project will determine in prospective longitudinal fashion the appropriate level of blood pressure control in HBP ADPKD patients. Secondly, since lVH also occurs in normotensive ADPKD patients, factors other than HBP or the ADPKD gene may play a role in the development of lVH in ADPKD patients. Given that activation of the renin-angiotensin-aldosterone axis is important in ADPKD and that the deletion polymorphism of the angiotensin converting enzyme gene is associated with LVH, normotensive and HBP ADPKD patients with and without LVH will be studied with regard to the frequency of this genotype. As well, given that hypertension in the unaffected parent is associated with earlier and more frequent HBP in ADPKD patients, the frequency of the angiotensinogen gene variant M235T will also be studied with regard to onset of hypertension and frequency of preeclampsia in ADPKD patients.

高血压通常发生在常染色体的自然史中主要的多囊性肾脏疾病（ADPKD）。高血压（HBP）已经证明对患者和肾脏结局产生不利影响 ADPKD。此外，左心室肥大（LVH），已知的危险因素对于心血管死亡率和猝死，HBP经常发生 ADPKD患者。目前尚不清楚最佳水平是什么 HBP ADPKD患者的血压降低，以最大程度地减少肾脏损失功能或反向LVH。鉴于高血压是最重要的可治疗的变量影响ADPKD中的肾脏和患者结果，这项目将以准纵向方式确定适当的 HBP ADPKD患者的血压控制水平。其次，自LVH以来还发生在正常的ADPKD患者中，HBP以外的其他因素 ADPKD基因可能在ADPKD患者的LVH发展中发挥作用。鉴于肾素 - 血管紧张素 - 醛固酮轴的激活为在ADPKD和血管紧张素的缺失多态性中很重要转化酶基因与LVH，正常性和HBP ADPKD有关有和没有LVH的患者将在频率方面进行研究该基因型。同样，鉴于未受影响的高血压父母与ADPKD患者的早期和更频繁的HBP相关联，血管紧张素基因基因变体M235T的频率也将是研究了高血压的发作和先兆子痫的频率在ADPKD患者中。